. [eighty two] to assess the efficacy, security and tolerability of Cannabidiol as an adjunct therapy in addition to anti-epileptic medicines about the clients struggling from tuberous sclerosis advanced whose most popular neurological symptom is epilepsy. On this clinical demo analyze, just after therapy with Cannabidiol, responder fee from the pe